Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Description

To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.

Conditions

Mast Cell Activation Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.

A 24-week, Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-range Finding Phase II Study to Compare Efficacy and Safety of Oral Masitinib to Placebo in Treatment of Patients With Severe Mast Cell Activation Syndrome (MCAS) With Handicap Unresponsive to Optimal Symptomatic Treatment

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Condition
Mast Cell Activation Syndrome
Intervention / Treatment

-

Contacts and Locations

Weldon Spring

St Charles Clinical Research, Weldon Spring, Missouri, United States, 63304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 75 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    AB Science,

    Julien Rossignol, MD, PRINCIPAL_INVESTIGATOR, Reference Centre for Mastocytosis (CEREMAST), Necker Hospital, Paris, France

    Study Record Dates

    2024-12-31